Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 367,198 |
|
|||||
| News | - | ||||||
| Day High | 1.32 | Low High |
|||||
| Day Low | 1.18 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immunic Inc | IMUX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.06 | -4.72% | 1.21 | 18:44:59 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.25 | 1.18 | 1.32 | 1.18 | 1.27 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,706 | 367,198 | $ 1.22 | $ 447,834 | - | 0.9451 - 3.11 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:32:03 | 80 | $ 1.18 | USD |
Immunic Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 107.91M | 89.93M | - | 0 | -93.61M | -1.04 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Immunic News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMUX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.40 | 1.46 | 1.18 | 1.32 | 303,873 | -0.19 | -13.57% |
| 1 Month | 1.35 | 1.46 | 1.17 | 1.30 | 265,722 | -0.14 | -10.37% |
| 3 Months | 1.13 | 1.64 | 1.125 | 1.30 | 614,189 | 0.08 | 7.08% |
| 6 Months | 1.20 | 1.73 | 0.9451 | 1.29 | 694,959 | 0.01 | 0.83% |
| 1 Year | 1.60 | 3.11 | 0.9451 | 1.63 | 811,525 | -0.39 | -24.38% |
| 3 Years | 14.38 | 15.65 | 0.9451 | 4.33 | 839,749 | -13.17 | -91.59% |
| 5 Years | 17.00 | 28.2138 | 0.9451 | 6.04 | 589,833 | -15.79 | -92.88% |
Immunic Description
| Immunic Inc is a clinical stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, IMU-935 is an inverse agonist of RORyt and IMU-856 targets the restoration of the intestinal barrier function. |
